| Literature DB >> 33032636 |
Haixiong Lin1, Xiaotong Wang2, Minling Huang1, Zige Li1, Zhen Shen3, Junjie Feng1, Huamei Chen1, Jingjing Wu1, Junyan Gao1, Zheng Wen4, Feng Huang5,6, Ziwei Jiang7.
Abstract
BACKGROUND: Bone defects can be seen everywhere in the clinic, but it is still a challenge for clinicians. Bibliometrics tool CiteSpace is based on the principle of "co-citation analysis theory" to reveal new technologies, hotspots, and trends in the medical field. In this study, CiteSpace was used to perform co-citation analysis on authors, countries (regions) and institutions, journals and cited journals, authors and cited literature, as well as keywords to reveal leaders, cooperative institutions, and research hotspots of bone defects and predict development trends.Entities:
Keywords: Bibliometrics; Bone defect; CiteSpace; Visual analysis; Web of Science
Mesh:
Year: 2020 PMID: 33032636 PMCID: PMC7545570 DOI: 10.1186/s13018-020-01973-3
Source DB: PubMed Journal: J Orthop Surg Res ISSN: 1749-799X Impact factor: 2.359
Fig. 1The number of annual publications
Study types of the included data
| No. | Study types | Amount | No. | Study types | Amount |
|---|---|---|---|---|---|
| 1 | Article | 4228 | 9 | Retracted publication | 6 |
| 2 | Meeting abstract | 616 | 10 | Retraction | 6 |
| 3 | Review | 128 | 11 | News item | 3 |
| 4 | Editorial material | 105 | 12 | Reprint | 3 |
| 5 | Letter | 62 | 13 | Book chapter | 1 |
| 6 | Correction | 37 | 14 | Correction addition | 1 |
| 7 | Early access | 10 | 15 | Discussion | 1 |
| 8 | Note | 7 |
Fig. 2Map of author’s cooperative relationship. Note: UIWON JUNG, Jung Ui-Won; CK KIM, Kim Chong-Kwan; AHMAD ORYAN, Oryan Ahmad; SH CHOI, Choi Seong-Ho; JOHN A JANSEN, Jansen John A; KS CHO, CHO KS; CS KIM, Kim Chang-Sung; YK LEE, Lee Yong-Keun; UME WIKESJO, Wikesjoe Ulf M. E.
Fig. 3Map of countries (regions) and institutions’ cooperative relationship. Note: Univ, university; PEOPLES R CHINA, People’s Republic of China
Fig. 4Top 10 countries (regions) and institutions with the strongest citation bursts. Note: Chinese Acad of Sci, Chinese Academy of Sciences; Univ, university; PEOPLES R CHINA, People’s Republic of China
Top 10 journals with the largest number of publications
| No. | Journal | Number of publications | Category (ranking) | Journal ranking of Thomson Reuters | 2019IF | 5-year IF |
|---|---|---|---|---|---|---|
| 1 | Tissue Engineering Part A* | 140 | Biotechnology & Applied Microbiology (44/161); Cell & Tissue Engineering (13/24); Cell Biology (89/190) | Q2 | 3.508 | 4.145 |
| 2 | Journal of Craniofacial Surgery | 136 | Surgery (183/210) | Q4 | 0.953 | 1.05 |
| 3 | Journal of Periodontology | 122 | Dentistry, Oral Surgery & Medicine (7/91) | Q1 | 3.742 | 3.614 |
| 4 | Bone | 119 | Endocrinology & Metabolism (36/143) | Q2 | 4.147 | 4.349 |
| 5 | Journal of Dental Research | 111 | Dentistry, Oral Surgery & Medicine (3/91) | Q1 | 4.914 | 5.844 |
| 6 | Journal of Bone and Mineral Research | 105 | Endocrinology & Metabolism (19/143) | Q1 | 5.854 | 5.985 |
| 7 | Clinical Oral Implants Research | 103 | Engineering, Biomedical (21/87) Dentistry, Oral Surgery & Medicine (8/91) | Q1 | 3.723 | 4.044 |
| 8 | Journal Of Biomedical Materials Research Part A | 88 | Materials Science, Biomaterials (16/38) Engineering, Biomedical (23/87) | Q2 | 3.525 | 3.469 |
| 9 | Biomaterials | 86 | Engineering, Biomedical (4/87) Materials Science, Biomaterials (1/38) | Q1 | 10.317 | 9.656 |
| 10 | Journal Of Biomedical Materials Research Part B Applied Biomaterials | 79 | Engineering, Biomedical (35/87) Materials Science, Biomaterials (23/38) | Q2 | 2.831 | 2.882 |
*Tissue Engineering Part A only have 2017IF
Fig. 5Map of journal co-citation. Note: Clin Orthop Relat R, Clinical Orthopaedics and Related Research; J Bone Joint Surg AM, Journal of Bone and Joint Surgery-American Volume; J Biomed Mater Res A, Journal of Biomedical Materials Research Part A; Clin Orthop Relat R, Clinical Orthopaedics and Related Research; J Periodontol, Journal of Periodontology
Fig. 6Map of author and reference co-citation
Top 5 author and reference co-citation
| No. | Frequency | Study types | Cited reference | Author (year of publication) |
|---|---|---|---|---|
| 1 | 57 | Article | Evaluation of bone regeneration using the rat critical size calvarial defect | SPICER PP (2012) [ |
| 2 | 47 | Article | The concept of induced membrane for reconstruction of long bone defects | MASQUELET AC (2010) [ |
| 3 | 47 | Review | Bone regeneration: current concepts and future directions | DIMITRIOU R (2011) [ |
| 4 | 41 | Review | Bone regenerative medicine: classic options, novel strategies, and future directions | ORYAN A (2014) [ |
| 5 | 40 | Review | Osteogenesis and angiogenesis: the potential for engineering bone | KANCZLER JM (2008) [ |
Fig. 7Map of keywords co-citation
Fig. 8Top 15 keywords in the burst value from 2010 to 2019
Cluster analysis of keywords
| Cluster ID | Keywords (positive likelihood ratio, P) | Content |
|---|---|---|
| 1 | management (11.22, 0.001); bone graft (8.98, 0.005); reconstruction (8.98, 0.005); bone regeneration (7.43, 0.01); allograft (6.78, 0.01); rat (6.2, 0.05); in vitro (5.63, 0.05); impaction bone grafting (5.6, 0.05); augmentation (5.6, 0.05); transport (5.6, 0.05); vascularized fibular graft (5.6, 0.05); children (5.6, 0.05); lumbar hernia (5.6, 0.05); dental implant (5.6, 0.05); bone tissue engineering (4.49, 0.05); periodontal regeneration (4.49, 0.05); calvarial defect (4.49, 0.05); marrow (4.47, 0.05); model (4.47, 0.05); guided tissue regeneration (4.31, 0.05); bone defect (3.91, 0.05) | Management of bone graft |
| 2 | bone regeneration (17.05, 1.0E-4); periodontal regeneration (13.4, 0.001); mandibular molar (10.81, 0.005); guided tissue regeneration (8.64, 0.005); freeze dried bone (7.2, 0.01); clinical evaluation (7.2, 0.01); alveolar bone fill (7.2, 0.01); radiography (7.2, 0.01); reconstructive osseous surgery (7.2, 0.01); membranes artificial (7.2, 0.01); intrabony defects (7.2, 0.01); osseous grafting (7.2, 0.01); peri-implantitis (6.67, 0.01) | Dental bone regeneration technology |
| 3 | rat (15.58, 1.0E-4); demineralized bone (14.88, 0.001); purification (10.55, 0.005); induction (9.9, 0.005); composite (9.9, 0.005); osteogenin (9.9, 0.005); bone freeze-dried (6.26, 0.05); porous hydroxyapatite (6.26, 0.05); inductive protein (6.26, 0.05); rabbit (6.01, 0.05); osteoblast (4.94, 0.05); matrix (4.94, 0.05); osteogenic effect (4.94, 0.05); periradicular surgery (4.94, 0.05); fibrin collagen paste (4.94, 0.05); decalcified bone (4.94, 0.05); hormone (4.94, 0.05); bone/demineralized (4.94, 0.05); nasal tip (4.94, 0.05); local application (4.94, 0.05); periodontitis therapy (4.94, 0.05); male animal (4.94, 0.05); e-ptfe (4.94, 0.05); parietal bone (4.94, 0.05); gentamicin (4.94, 0.05); bioerodible polyorthoester (4.94, 0.05); tetracycline therapeutic use (4.94, 0.05); mesenchymal cell (4.94, 0.05); artificial membranes (4.94, 0.05); skull (4.94, 0.05); gastric pentadecapeptide bpc-157 (4.94, 0.05); doxycycline (4.94, 0.05); family member (4.94, 0.05); skull surgery (4.94, 0.05); periodontal pockets therapy (4.94, 0.05); periodontal diseases therapy (4.94, 0.05); segmental bone defects (4.94, 0.05); calvarial bone defects (4.94, 0.05); experimental (4.94, 0.05); autologous cortical bone (4.94, 0.05); polytetrafluoroethylene (therapeutic use) (4.94, 0.05); octacalcium phosphate (4.94, 0.05); substitute (4.94, 0.05); capacity (4.94, 0.05); intramuscular application (4.94, 0.05); stomach (4.94, 0.05); prostaglandin (4.94, 0.05); male rats (4.94, 0.05); attachment (4.94, 0.05); morphogenetic protein (4.71, 0.05); implantation (4.71, 0.05) | Bone formation in rats with bone defects |
| 4 | bone tissue engineering (19.2, 1.0E-4); angiogenesis (14.38, 0.001); guided tissue regeneration (12.29, 0.001); calvarial defect (11.47, 0.001); membranes (10.82, 0.005); osteogenic differentiation (9.57, 0.005); mesenchymal stem cell (6.81, 0.01); in vitro (6.71, 0.01); bone graft (5.71, 0.05); reconstruction (5.71, 0.05); periodontal diseases/therapy (5.71, 0.05); demineralized bone matrix (5.29, 0.05); scaffold (5.07, 0.05); hydroxyapatite/therapeutic use (4.99, 0.05); polycaprolactone (4.78, 0.05); beta tricalcium phosphate (4.78, 0.05); marrow stromal cell (4.78, 0.05); vivo (4.78, 0.05); femoral defect (4.78, 0.05); articular cartilage (4.78, 0.05); vitro (4.78, 0.05); proliferation (4.78, 0.05); bmscs (4.78, 0.05); hydroxyapatite scaffold (4.78, 0.05); mandibular reconstruction (4.78, 0.05); delivery (4.78, 0.05); guided bone regeneration (4.61, 0.05); bone substitutes (4.26, 0.05); periodontal diseases/surgery (4.26, 0.05); barrier (4.26, 0.05); outcome assessment (4.26, 0.05) | Application of bone tissue engineering such as biological scaffolds in vascularization and osteogenic differentiation of bone defects |
| 5 | membranes (21.65, 1.0E-4); guided bone regeneration (12.99, 0.001); bioabsorbable (11.02, 0.001); comparison studies (11.02, 0.001); barrier (7.52, 0.01); mandible (6.56, 0.05); grafts bone (6.56, 0.05); periodontal diseases/therapy (5.57, 0.05); implant-associated defect (5.1, 0.05); component (5.1, 0.05); cell binding peptide (5.1, 0.05); oral implants (5.1, 0.05); bone allografts (5.1, 0.05); membranes bioabsorbable (5.1, 0.05); gingival recession/therapy (5.1, 0.05); freeze-dried bone (5.1, 0.05); defect (5.1, 0.05); calcium sulfate/therapeutic use (5.1, 0.05); intraosseous defects (5.1, 0.05); gap bone filler (5.1, 0.05); gingival recession/surgery (5.1, 0.05); follow-up studies (5.1, 0.05); gtam (5.1, 0.05); gene expression (5.1, 0.05); controlled (5.1, 0.05); collagen synthesis (5.1, 0.05); laminar bone (5.1, 0.05); dogs (5.1, 0.05); graft healing (5.1, 0.05); implants (5.1, 0.05); osseointegration (5.1, 0.05); acetabulum (5.1, 0.05); osteocalcin (5.1, 0.05); lllt (5.1, 0.05); polytetrafluoroethylene/therapeutic use (5.1, 0.05); alveolar bone loss (5.1, 0.05); resorbable membrane (5.1, 0.05); graft shape (5.1, 0.05); mta (5.1, 0.05); lyodura (5.1, 0.05); finite element analysis (5.1, 0.05); grafts (5, 0.05); bone (4.86, 0.05); guided tissue regeneration (4.02, 0.05); autograft (3.97, 0.05); cancellous bone (3.97, 0.05); clinical trials (3.97, 0.05); artificial (3.97, 0.05); repair (3.76, 0.1) | Membrane-induced bone regeneration |
| 6 | hydroxyapatite (14.12, 0.001); osteoconduction (10.26, 0.005); mechanical properties (10.26, 0.005); mechanical property (6.6, 0.05); carbon nanotube (5.12, 0.05); bioactive glas (5.12, 0.05); extrusion free-forming (5.12, 0.05); osteoinduction (5.12, 0.05); arthroplasty (5.12, 0.05); haemocompatibility (5.12, 0.05); repetitive acidic amino acid (5.12, 0.05); composite and powder materials (5.12, 0.05); nanocrystalline hydroxyapatite (5.12, 0.05); bone morphogenic protein 2-related peptide (5.12, 0.05); collagen scaffold (5.12, 0.05); microsphere (5.12, 0.05); nanowire (5.12, 0.05); bone cement (5.12, 0.05); porous tantalum (5.12, 0.05); tetracycline (5.12, 0.05); production process (5.12, 0.05); structure (5.12, 0.05); carbon implants (5.12, 0.05); led phototherapy (5.12, 0.05); nano-hydroxyapatite (5.12, 0.05); bone-implant contact (5.12, 0.05); cement (5.12, 0.05); strength (5.12, 0.05); bioglass (5.12, 0.05); cross linking (5.12, 0.05); nanostructured materials (5.12, 0.05); normal bone (5.12, 0.05); tgf-beta 1 (5.12, 0.05); membrane technique (5.12, 0.05); sintering temperature (5.12, 0.05); silk fibroin (5.12, 0.05); bioactive glass (5.12, 0.05); pattern (5.12, 0.05); slurry-compounding process (5.12, 0.05); drug delivery (5.12, 0.05); new bone formation (5.12, 0.05); hip (5.12, 0.05); weight bearing fracture (5.12, 0.05); early vascularization (5.12, 0.05); lactosorb (5.12, 0.05); tibial fracture (5.03, 0.05); biomaterials (4.01, 0.05); biomaterial (4.01, 0.05) | Nanomaterials induce bone formation |
| 7 | extracellular matrix (14.6, 0.001); cartilage (12.45, 0.001); bovine bone (8.91, 0.005); collagen (8.91, 0.005); beta family (8.91, 0.005); mandibular defects (6.3, 0.05); smooth muscle cell (6.3, 0.05); osteogenic protein (6.3, 0.05); camurati engelmann disease (6.3, 0.05); human patients (6.3, 0.05); ectopic induction (6.3, 0.05); transforming growth factor beta 1 (6.3, 0.05); water soluble protein (6.3, 0.05); plate (6.3, 0.05); member (6.3, 0.05); bone induction (6.3, 0.05); colony-forming unit fibroblastic (6.3, 0.05); increased expression (6.3, 0.05); mandibular fracture (6.3, 0.05); cartilage differentiation (6.3, 0.05); hydroxyapatite granules (6.3, 0.05); delivery vehicle (6.3, 0.05); biglycan (6.3, 0.05); osteoinductive implants (6.3, 0.05); fibroblast cells (6.3, 0.05); screw (6.3, 0.05); indian hedgehog (6.3, 0.05); 8 cysteine repeat (6.3, 0.05); new bone (6.3, 0.05); fibronectin (6.3, 0.05) | Extracellular matrix induces cartilage formation and differentiation |
Fig. 9Timezone view of keywords. (The node indicates that the keyword appears for the first time in large numbers, and the arc indicates that it is cited)